Alignment Healthcare Shares Slide 9% After Q1 Beat on Membership Growth and Raised Outlook

Earnings Beat

Alignment Healthcare delivered a solid first‑quarter performance. Non‑GAAP earnings per share came in at $1.45, crushing the Street’s estimate of $0.02. GAAP EPS was flat at $0.00, reflecting higher equity‑based compensation and depreciation. Revenue rose 33.3% YoY to $1.235 billion, edging past the consensus estimate of $1.22 billion.

The company highlighted a 30.9% jump in Medicare Advantage membership to roughly 284,800 members, underpinning the top‑line growth. Adjusted gross profit climbed 36.1% YoY to $145.9 million, and adjusted EBITDA surged 87.6% YoY to $37.9 million, delivering a 3.1% margin.

Guidance & Outlook

Management raised the midpoint of its guidance across the board. For the June‑ended quarter, revenue is now projected at $1.295‑$1.315 billion, and full‑year 2026 revenue is forecast at $5.16‑$5.205 billion. Adjusted gross profit guidance moves to $167‑$177 million for Q2 and $620‑$650 million for the year, while adjusted EBITDA is expected at $50‑$60 million in the quarter and $138‑$163 million annually.

The company also lifted its membership target to 288‑290 k for Q2 and 294‑299 k for year‑end, signaling confidence in continued enrollment momentum.

Conference Call Highlights

CEO John Kao emphasized disciplined growth, saying the firm “expanded profitability by executing across sales, clinical operations and cost management, even as the Medicare Advantage environment continues to change.” He pointed to ongoing investments in technology and people as catalysts for scaling the business and hitting “embedded earnings potential.”

CFO remarks highlighted a $12.6 million reduction in equity‑based compensation within SG&A and a $7.8 million decline in depreciation & amortization, which helped lift adjusted margins.

Market Reaction & Analyst Take

Despite the earnings beat, the stock dropped 8.94% to $20.52 in after‑hours trading, marking the steepest decline since Q4 2025. Analysts cited three main concerns:

1. GAAP earnings flat – the zero GAAP EPS raised questions about cash profitability.

2. Guidance still below consensus – while the midpoint was raised, the upper range remains modest relative to peers, prompting a cautious outlook.

3. Medicare Advantage volatility – ongoing policy uncertainty in the MA market weighed on sentiment.

MarketBeat and WTOP reported that several analysts downgraded the stock to “Neutral” from “Buy,” while others trimmed price targets from $24 to $22, reflecting the mixed view of growth versus profitability.

Investor Takeaways

Alignment Healthcare posted a strong top‑line and membership surge, but the market punished the stock on GAAP earnings weakness and guidance that, while improved, still lags peer expectations. Investors will be watching the June quarter closely for evidence that the raised outlook translates into sustainable cash earnings.

---

All figures are from the company’s Q1 2026 8‑K filing and post‑market data as of 5:33 PM ET.